InMed Pharmaceuticals is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
Clinical trials: Yes.
The company is active with 4 candidates in the fields of dermatology, ocular conditions and Alzheimer’s disease.
The company is focused on slowing the progress of and reversing Alzheimer’s with rare cannabinoids indentified by the company that are highly lipophilic and can easily cross the blood-brain barrier.
The company has applied for 70+ patents within – NCEs/formulations, manufacturing methods and methods of use with 2 each granted for the 2 latter categories.
The company’s pharmaceutical drug development program by the name of IMN-901 shows the potential for targeting biological pathways associated with Alzheimer’s.
SUBSIDIARIES:
Bay Medica is a B2B supplier specializing in the manufacturing and commercialization of rare cannabinoids and sells CBC, CBDV, THCV and CBT in wholesale for the health and wellness market.
NEWS & PARTNERSHIPS:
2015
The company formed an exclusive strategic collaboration with Dr. Tamás Bíró of the University of Debrecen, Hungary for the development of novel phytocannabinoid therapies for the treatment of ocular allergies.
The company was awarded a grant from Mitacs for the further development of the company’s proprietary nanoparticle-based delivery system for their leading drug candidate CTI-085 for glaucoma in collaboration with members of the Department of Chemical & Biological Engineering at the University of British Columbia.
2017
The company signed a R&D collaboration with Atera where Atera will develop 3D human skin models of Epidermolysis Bullosa for the evalution of the in vitro drug efficacy of InMed’s lead compound, INM-750. Atera will also investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels on in vitro 3D reconstructed human full thickness skin models composed of both normal and EB-derived skin cells.
The company announced the signing of an agreement with Pharmaseed for the development of a a final formulation for InMed’s lead compound, INM-750. Pharmaseed will develop a final formulation for INM-750 for continued R&D including IND-enabling pharmacology and toxicology studies as well as subsequent clinical studies while at the same time working on the development of assay methods for manufacturing, stability, quality assurance and other analytical methods.
2018
The company entered into a research agreement with the National Research Council of Canada for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli.
The company received funding of up to 500,000 CAD from the government of Canada to support InMed’s ongoing R&D efforts in cannabinoid biosynthesis.
The University of British Columbia was approved to receive a grant of 136,000 CAD for its collaborative efforts with InMed in the biosynthesis of cannabinoids.
2020
The company entered into a broad reciprocal research collaboration with BayMedica to explore synergies between technologies owned by the two companies. BayMedica is given access to specific elements of InMed’s proprietary IntegraSyn platform for the production of cannabinoids with the intent of assessing the potential of 1 or more of InMed’s high-efficiency enzyme gene sequences in BayMedica’s systems for the production of the cannabinoids in BayMedica’s catalogue. InMed will undertake preclinical investigation of numerous therapeutic compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs. Utilizing its validated assays and assessment criteria, InMed will also explore the therapeutic potential of specific analog compounds in selected disease models in the field of neuroprotection as compared to naturally occurring cannabinoids. Should the initial research phases of the individual projects defined under the agreement achieve positive and meaningful results, the Collaborative Research Agreement provides a mechanism to license the other party’s technology.
The company secured a worldwide exclusive license from EyeCRO for its MiDROPS (Microemulsion Drug Ocular Penetration System), an eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. The agreement gives the company the right to develop and commercialize prospective therapeutic formulations combining MiDROPS with any and all cannabinoid molecules. EyeCRO will receive consideration in the form of scheduled payments upon the achievement of certain clinical, regulatory and commercial milestones, paid in cash and a nominal amount of securities of InMed as well as a low, single digit royalty on any commercial sales of InMed therapeutic products incorporating MiDROPS. The agreement considers and protects each company’s respective intellectual property and patent rights and defines specific provisions for consideration of any new intellectual property that may arise through future development.
The company became the first to investigate CBN’s therapeutic potential in human clinical trials.
The company announced a coopeartion with Almac Group for the development of a streamlined cannabinoid manufacturing process, specifically optimizing the upstream cannabinoid assembly processes as well as downstream purification, to achieve cost efficient, GMP-grade active pharmaceutical ingredients for prescription-based medications.
2021
In april, the company achieved a 2g/l cannabinoid yield with IntegraSyn and in June, the company achieved a 5g/l cannabinoid yield with IntegraSyn.
The company acquired BayMedica.
2022
The company announced that they will be providing THCV to Trokie for the manufacturing of a formulated proprietary lozenge to supply to Radicle Science’s Radicle Energy Study for the assessment of THCV and its effects on energy, focus/attention, appetite and weight/BMI.
The company expanded its rare cannabinoid product portfolio by launching B2B sales of CBT (Cannabicitran), CBDV (Cannabidivarin) and THCV (Tetrahydrocannabivarin).
The company initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy, in the laboratory of Dr. Mauro Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.
2024
Pre-clinical studies of INM-901 showed promising oral delivery with the oral formulation effectively crossing the blood-brain barrier and achieving therapeutic brain levels for Alzheimer’s treatment.
2025
The company was granted Patent No. 417531 in Mexico.